CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Maruho Medical

We are focused on improving sports medicine outcomes by providing innovative technologies and supporting surgeons with integrity, collaboration, and a commitment to excellence. We achieve this by providing medical devices and services that are unique, highly effective, reliable, easy to learn and cost-effective. At present, maruho medical offers a comprehensive portfolio of orthopedic surgery products that complement arthroscopic shoulder, knee, hip, and extremity procedures.

Nautilus Biosciences Canada

Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeryon Labs Inc

Aeryon Labs Inc is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antigen Laboratories Inc

Antigen Laboratories Inc is a Liberty, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.